The effect of tiotropium in COPD complicated with asthma Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease Year: 2015
QVA149 provides superior peak lung function in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Nebulized bronchodilator therapy in stable COPD – effect on quality of life and spirometry Source: Eur Respir J 2006; 28: Suppl. 50, 64s Year: 2006
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
The effect of tiotropium on exacerbations and airflow in patients with COPD Source: Eur Respir J 2006; 27: 547-555 Year: 2006
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
A realistic study assessing inhaled treatment compliance in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001
Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013